Correction: Tatsumi et al. Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis. J. Clin. Med. 2023, 12, 7165

Text Correction

There was an error in the original publication [1]. “The authors mentioned ‘anti-IL-6 antibody’ in two places, which was an error and instead should be ‘anti-IL-6 receptor antibody’. The authors have also changed reference 23 accordingly to the following:

23. Naka T, Fujimoto M. LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. Immunol Med. 2018 Jun;41(2):62–67. doi: 10.1080/13497413.2018.1481582.” [2].

A correction has been made to “Introduction”, “Paragraph Number 3”:

“Another factor that has to be taken into consideration is the interaction between biomarkers. For example, CRP is less likely to be elevated under anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis since the release of CRP is affected by IL-6; therefore, it is not useful for assessing disease activity [23]. Similarly, LRG is induced by stimuli such as TNFα [12]; therefore, under the administration of anti-TNFα antibody preparations, which are typical biologics for the treatment of refractory UC, the reactivity of LRG may be slowed down with a decrease in TNFα. However, there have been no reports on LRG reactivity in patients with UC receiving anti-TNFα antibody agents.”

A correction has been made to “Discussion”, “Paragraph Number 3”:

“Certain biomarkers may be undetectable in patients treated with biological agents. It is known that serum CRP, which is induced by IL-6, is less likely to be elevated in patients with rheumatoid arthritis who are being treated with anti-IL-6 receptor antibody preparations [23]. Similarly, since LRG is induced by stimulation from inflammatory cytokines such as TNFα, IL-1β, and IL-6, this study examined whether LRG is less likely to be detected in patients with UC receiving anti-TNF antibody preparations. No particular change in LRG reactivity was observed in these patients. These results suggest that LRG is a useful marker of disease activity even in patients receiving anti-TNF antibody preparations.”

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.